Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerGlobeNewsWire • Thursday
Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerGlobeNewsWire • Tuesday
City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerBusiness Wire • Tuesday
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal CancerGlobeNewsWire • 11/09/26
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal CancerGlobeNewsWire • 10/28/26
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceGlobeNewsWire • 10/27/26
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual ConferenceGlobeNewsWire • 10/14/26
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerGlobeNewsWire • 09/22/26
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® TechnologyGlobeNewsWire • 09/10/26
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate CandidatesGlobeNewsWire • 09/09/26
Adagene Reports Six Months 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/12/26
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal CancerMarketBeat • 05/19/26
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor TypesGlobeNewsWire • 04/17/26
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory BoardGlobeNewsWire • 04/14/26
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)GlobeNewsWire • 04/02/26
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of ResponseGlobeNewsWire • 04/02/26